Biogen Inc. (BIIB) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Biogen Inc. (BIIB) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How BIIB Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $9.89B | 75.7% | 15.4% | $1.29B | $2.05B | 6% |
| FY 2024 | $9.68B | 76.1% | 19.9% | $1.63B | $2.72B | 8.1% |
| FY 2023 | $9.84B | 44% | 13.9% | $1.16B | $1.10B | 8.8% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring BIIB)
- ✓Live walkthrough of BIIB's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
BIIB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +2.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BIIB today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BIIB. Explore sector supply chains on /butterfly.
BIIB Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Biogen Inc. (BIIB)?
In FY 2025 (10-K), BIIB converted $9.9B of revenue into a 75.7% gross margin, 15.4% operating margin, and $2.1B in free cash flow (20.7% FCF margin).